Peter R. Dottino, MD, professor of obstetrics, gynecology and reproductive science, Mount Sinai Hospital, discusses targeted therapies for patients with ovarian cancer.

There are PARP inhibitors and VEGF inhibitors are targeted therapies that are available today, but others are being investigated in phase I/II trials that will be potentially of use, explains Dottino.

According to Dottino in a study investigating 

-mutated patients using AZD1775 with carboplatin in platinum-refractory patients, a 46% response rate was observed.

Videos

Dr. Dottino on Targeted Therapies in Ovarian Cancer

Peter R. Dottino, MD, professor of obstetrics, gynecology and reproductive science, Mount Sinai Hospital, discusses molecular techniques used to determine ovarian cancer following treatment with chemotherapy.

Researchers out of Mount Sinai out of their 10-year biobank to explore tumors to determine what the genetic make-up of the primary tumor, the recurrent tumor, and whether they can predict and find the same mutations in the primary tumor as in "second-look" washings, Dottino says. Using a 56-gene panel with next-generation sequencing, it was discovered that 5 patients had positive second-looks, with mutations in all washes. Three out of 5 patients who were classed as negative second-looks were later determined to still carry deleterious 

 mutations. These patients went on to have recurrent disease. 

This confirms that there is a heterogeneity to ovarian cancer, Dottino explains. 

Peter R. Dottino, MD

Articles

Dr. Dottino on Targeted Therapies in Ovarian Cancer

Dr. Dottino on Molecular Detection of Recurrent Ovarian Cancer